[1] Pitt C, Goodman C, Hanson K. Economic evaluation in global perspective: a bibliometric analysis of the recent literature. Health Econ 2016;25(Suppl 1):9 − 28. http://dx.doi.org/10.1002/hec.3305CrossRef
[2] Butt T, Liu GG, Kim DD, Neumann PJ. Taking stock of cost-effectiveness analysis of healthcare in China. BMJ Glob Health 2019;4(3):e001418. http://dx.doi.org/10.1136/bmjgh-2019-001418CrossRef
[3] Eddama O, Coast J. A systematic review of the use of economic evaluation in local decision-making. Health Policy 2008;86(2−3):129 − 41. http://dx.doi.org/10.1016/j.healthpol.2007.11.010CrossRef
[4] CDC. Framework for program evaluation in public health. MMWR Morb Mortal Wkly Rep 1999;48(RR11):1 − 40. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4811a1.htm.https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4811a1.htm
[5] U.S. Congress, Office of Technology Assessment. Identifying health technologies that work: searching for evidence, OTA-H-608. Washington, DC: US Government Printing Office. 1994. https://www.princeton.edu/~ota/disk1/1994/9414/9414.PDF.https://www.princeton.edu/~ota/disk1/1994/9414/9414.PDF
[6] Teutsch SM, Harris JR. Introduction. In: Haddix AC, Teutsch SM, Corso PS, editors. Prevention effectiveness: a guide to decision analysis and economic evaluation. 2nd ed. Oxford: Oxford University Press. 2003; p. 1 − 10.
[7] Roy K, Chen Z, Haddix AC. Prevention effectiveness. In: Scutchfield FD, Keck CW, editors. Principles of public health practice. 3rd ed. Clifton Park, NY: Delmar Cengage Learning. 2009; p. 307 − 25. https://vufind.carli.illinois.edu/vf-uic/Record/uic_2185949/TOC.https://vufind.carli.illinois.edu/vf-uic/Record/uic_2185949/TOC
[8] Haddix AC, Corso PS, Gorsky RD. Costs. In: Haddix AC, Teutsch SM, Corso PS, editors. Prevention effectiveness: a guide to decision analysis and economic evaluation. 2nd ed. Oxford: Oxford University Press. 2003.
[9] Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, et al. Future directions for cost-effectiveness analyses in health and medicine. Med Decis Making 2018;38(7):767 − 77. http://dx.doi.org/10.1177/0272989X18798833CrossRef
[10] Skelton AG, Meltzer MI. 20 Years of Public Health Economics and Decision Sciences at the US centers for disease control and prevention: the CDC Steven M. Teutsch prevention effectiveness fellowship, 1995-2015. J Public Health Manag Pract 2017;23(4):e14 − 21. http://dx.doi.org/10.1097/PHH.0000000000000437.http://dx.doi.org/10.1097/PHH.0000000000000437
[11] Grosse SD, Berry RJ, Mick Tilford J, Kucik JE, Waitzman NJ. Retrospective assessment of cost savings from prevention: folic acid fortification and spina bifida in the U.S. Am J Prev Med 2016;50(S5):S74 − 80. http://dx.doi.org/10.1016/j.amepre.2015.10.012CrossRef
[12] Scharff RL, Besser J, Sharp DJ, Jones TF, Gerner-Smidt P, Hedberg CW. An economic evaluation of PulseNet: a network for foodborne disease surveillance. Am J Prev Med 2016;50(S5):S66 − 73. http://dx.doi.org/10.1016/j.amepre.2015.09.018CrossRef
[13] Yin ZD, Beeler Asay GR, Zhang L, Li YX, Zuo SY, Hutin YJ, et al. An economic evaluation of the use of Japanese encephalitis vaccine in the expanded program of immunization of Guizhou province, China. Vaccine 2012;30(37):5569 − 77. http://dx.doi.org/10.1016/j.vaccine.2012.05.068CrossRef
[14] Zhou L, Situ SJ, Feng ZJ, Atkins CY, Fung IC, Xu Z, et al. Cost-effectiveness of alternative strategies for annual influenza vaccination among children aged 6 months to 14 years in four provinces in China. PLoS One 2014;9(1):e87590. http://dx.doi.org/10.1371/journal.pone.0087590CrossRef
[15] Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 2010;51(2):405 − 14. http://dx.doi.org/10.1002/hep.23310CrossRef
[16] Liu XQ, Li CP, Gong H, Cui Z, Fan LL, Yu WH, et al. An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study. BMC Public Health 2013;13:729. http://dx.doi.org/10.1186/1471-2458-13-729CrossRef
[17] Liu GG, Wu HY, Li MH, Gao C, Luo N. Chinese time trade-off values for EQ-5D health states. Value Health 2014;17(5):597 − 604. http://dx.doi.org/10.1016/j.jval.2014.05.007CrossRef
[18] Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services (HHS). Medical examination of aliens-removal of human immunodeficiency virus (HIV) infection from definition of communicable disease of public health significance. Final rule. Fed Regist 2009;74(210):56547 − 62. https://www.ncbi.nlm.nih.gov/pubmed/20166276.https://www.ncbi.nlm.nih.gov/pubmed/20166276
[19] Cutler DM, Jessup AI, Kenkel DS, Starr MA. Economic approaches to estimating benefits of regulations affecting addictive goods. Am J Prev Med 2016;50(S5):S20 − 6. http://dx.doi.org/10.1016/j.amepre.2015.12.002CrossRef
[20] Economics Staff, Office of Economics and Analysis, Office of Policy, Legislation, and International Affairs, Office of the Commissioner. Tobacco Products; Required Warnings for Cigarette Packages and Advertisements. Docket No. FDA-2019-N-3065. Food and Drug Administration. 2019. https://www.fda.gov/media/130053/download.https://www.fda.gov/media/130053/download
[21] Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, et al. The international decision support initiative reference case for economic evaluation: an aid to thought. Value Health 2016;19(8):921 − 8. http://dx.doi.org/10.1016/j.jval.2016.04.015CrossRef
[22] Hammitt JK, Robinson LA. The income elasticity of the value per statistical life: transferring estimates between high and low income populations. J Benefit-Cost Anal 2011;2(1):1 − 29. http://dx.doi.org/10.2202/2152-2812.1009CrossRef